EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Photoswitchable Diazocine Derivative for Adenosine A 3 Receptor Activation in Psoriasis

Marc López-Cano, Mirko Scortichini, Dilip K Tosh, Veronica Salmaso, Tongil Ko iD, Glòria Salort, Ingrid Filgaira iD, Concepció Soler, Dirk Trauner iD, Jordi Hernando iD, Kenneth A Jacobson iD, Francisco Ciruela iD

Journal of the American Chemical Society · 08.01.2025 · 147 (1) · 874-879

DOI: 10.1021/jacs.4c13558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 16.12.2024. Verfasst von Marc López-Cano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, Univer…. Hauptthemen laut MEDLINE: Adenosine A3 Receptor Agonists, Psoriasis. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, Ministerio de Ciencia, Innovaci?n y Universidades, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incorporating photoisomerizable moieties within drugs offers the possibility of rapid and reversible light-dependent switching between active and inactive configurations. Here, we developed a photoswitchable adenosine A3 receptor (A3R) agonist that confers optical control on this G protein-coupled receptor through noninvasive topical skin irradiation in an animal model of psoriasis. This was achieved by covalently bonding an adenosine-5'-methyluronamide moiety to a diazocine photochrome, whose singular photoswitching properties facilitated repeated interconversion between a thermally stable, biologically inactive Z agonist form and a photoinduced, pharmacologically active E configuration. As a result, our photoswitchable agonist allowed the precise modulation of A3R function both in vitro and in vivo, which led to a clear light-controlled pharmacotherapeutic effect on mouse skin lesions. This breakthrough not only demonstrates the potential of diazocine photoswitches for in vivo photopharmacology but also paves the way for the development of new strategies for skin-related diseases that require localized and temporally controlled drug action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine A3 Receptor AgonistsPsoriasisAnimalsMiceReceptor, Adenosine A3HumansPhotochemical ProcessesMolecular Structure

Substanzen

Adenosine A3 Receptor AgonistsReceptor, Adenosine A3

Autor:innen und Institutionen

  • Pharmacology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, L'Hospitalet de Llobregat 08907, Spain.
  • Neuropharmacology and Pain Group, Neuroscience Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat 08907, Spain.
  • Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Department of Chemistry, University of Pennsylvania College of Arts and Sciences, Philadelphia, Pennsylvania 19104, United States.
  • Immunology Unit, Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, University of Barcelona, L'Hospitalet de Llobregat 08907, Spain.
  • Immunity, Inflammation and Cancer Group, Oncology Program, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat 08907, Spain.

ORCID-Profile: Tongil Ko, Ingrid Filgaira, Dirk Trauner, Jordi Hernando, Kenneth A Jacobson, Francisco Ciruela

Förderung

  • Intramural NIH HHS
  • Ministerio de Ciencia, Innovaci?n y Universidades
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • NextGenerationEU
  • Generalitat de Catalunya
  • Universitat de Barcelona

Zitieren

APA

López-Cano, M., Scortichini, M., Tosh, D. K., Salmaso, V., Ko, T., Salort, G., Filgaira, I., Soler, C., Trauner, D., Hernando, J., Jacobson, K. A., & Ciruela, F. (2025). Photoswitchable Diazocine Derivative for Adenosine A 3 Receptor Activation in Psoriasis. Journal of the American Chemical Society, 147(1), 874-879. https://doi.org/10.1021/jacs.4c13558

Vancouver

López-Cano M, Scortichini M, Tosh DK, Salmaso V, Ko T, Salort G, et al. Photoswitchable Diazocine Derivative for Adenosine A 3 Receptor Activation in Psoriasis. Journal of the American Chemical Society. 2025;147(1):874-879. doi:10.1021/jacs.4c13558

BibTeX
@article{LpezCano2025,
  author = {López-Cano, Marc and Scortichini, Mirko and Tosh, Dilip K and Salmaso, Veronica and Ko, Tongil and Salort, Glòria and Filgaira, Ingrid and Soler, Concepció and Trauner, Dirk and Hernando, Jordi and Jacobson, Kenneth A and Ciruela, Francisco},
  title = {Photoswitchable Diazocine Derivative for Adenosine A 3 Receptor Activation in Psoriasis},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  volume = {147},
  number = {1},
  pages = {874--879},
  doi = {10.1021/jacs.4c13558}
}
Kostenlos starten →